Targeting histone abnormality in triple negative breast cancer

Abstract

During this funding period, Dr. Nancy E. Davidson moved to University of Washington at Seattle and transferred the Partnering PI toDr. Steffi Oesterreich at University of Pittsburgh. Dr. Oesterreich worked closely together with initiating PI, Dr. Yi Huang, to decipher how histone abnormality contributes to TNBC tumorigenesis and explore how to apply novel epigenetic agents in the most favorable combination strategy against TNBC. In the prior funding period, the joint team has revealed coordinated overexpression of HDAC5 and LSD1 proteins in clinical breast tumor specimens and identified that sulforaphane (SFN), a natural bioactive HDAC inhibitor, was able to destabilize LSD1 protein through down regulation ofHDAC5 expression. Combined use of SFN with a potent LSD1 inhibitor HCI-2509 significantly enhanced antineoplastic efficacy of SFN in MDA-MB-231xenografts in mice.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2017
Accession Number
AD1042906

Entities

People

  • Steffi Oesterreich

Organizations

  • University of Pittsburgh

Tags

DTIC Thesaurus Topics

  • Breast Cancer
  • Cell Physiological Processes
  • Cells
  • Enzyme Inhibitors
  • Health Services
  • Lymphatic Diseases
  • Medical Personnel
  • Neoplasms
  • Proteins
  • Statistical Analysis
  • Stem Cells
  • Tumor Cell Line

Fields of Study

  • Biology
  • Medicine

Readers

  • Molecular Biology and Genetics
  • Oncology (Cancer Research).
  • Research Science/Academic Research